MICOT PHARMA-B (02335): The first subject was enrolled in the Phase Ib/II clinical trial of MT1002 for the treatment of acute ischemic stroke.

MICOT PHARMA-B (02335) announces that the group's independently developed candidate drug MT1002 for the treatment of acute ischemic stroke (AIS) has successfully completed the first subject enrollment in Phase Ib/II clinical trial, marking the formal entry into the substantial execution phase of this key registration clinical research. This Phase Ib/II clinical trial is divided into two parts. The first part is a multicenter clinical study evaluating the safety, efficacy, and pharmacokinetic characteristics of MT1002 in patients with acute ischemic stroke. The second part is a multicenter, randomized, standard treatment-controlled clinical study evaluating the safety and efficacy of MT1002 in patients with acute ischemic stroke. The first subject enrollment mentioned in this announcement is the first subject enrolled in the first part of this Phase Ib/II clinical trial. Acute ischemic stroke refers to a clinical syndrome caused by sudden severe narrowing or occlusion of cerebral arteries due to various reasons, leading to local brain tissue ischemia, hypoxic necrosis, corresponding neurological deficits, and new cerebral infarction changes observed on head CT or MRI. It is the most common type of stroke. According to a review on the treatment of acute ischemic stroke in 2025, AIS accounts for 69.6% to 72.8% of new strokes in China. According to data from Moore Statistics, the market size of main treatment drugs for acute ischemic stroke in the acute phase in China has been over one hundred billion RMB in recent years, reaching 12.9 billion RMB in 2023.